Editor’s note

  • A double whammy for the sector?

    As expected, the August 30 meeting called by the Department of Pharmaceuticals (DoP) to discuss the Draft Pharmaceutical Policy 2017 saw a laundry list of...

  • Draft pharma policy: Old wine in a new bottle?

    The Draft Pharma Policy 2017 which was released for comments in mid-August, has an ambitious intent: to make drug pricing 'more poor oriented while retaining...

  • Surviving serialisation

    It was way back in 1963 that the US FDA finalised the first version of Good Manufacturing Practices (GMPs) for finished pharmaceuticals

  • India Pharma Inc’s tryst with destiny continues

    As we mark our 71st Independence Day this August 15, how far have we progressed on the medicines security front?

  • A wake up call for serialisation laggards

    Pharma companies exporting to the US market who had their eye on the November 2017 deadline to comply with the US Drug Supply Chain Security...

  • Racing against the GST deadline

    The May update on pharma channel sales was gloomy at best, according to AIOCD PharmaTrac

  • Dull Q4FY17 could be a blessing in disguise

    According to a report from CARE Ratings on the corporate performance of Q4FY17, the pharmaceuticals and drugs sector in India, growth in net sales in...

  • Towards sustainability

    Sustainability measures achieve the twin benefits of reducing operating costs while simultaneously meeting environmental goals

  • Bridging the skills gap

    Beleaguered by warning letters and import recalls, pharmaceutical companies in India seem to be finally investing in upskilling their employees

  • Passing the buck?

    Prime Minister Modi’s announcement that his government would ensure doctors prescribed generic medicines stirred a hornet’s nest

  • Does IP build or block?

    Its been 17 years since the World Intellectual Property Organisation (WIPO) started marking April 26 as World Intellectual Property Day

  • US-India relationship: Can it trump the odds?

    Affordable and efficient healthcare systems is listed out as an area chosen for “Growing Convergence, Collaboration & Cooperation between United States and India” in a...

  • Collaborate to conquer

    Two rulings in the space of as many days demonstrate the fine balance required of India’s legal system when it comes to the pharmaceutical sector

  • Evolving an ‘India First’ policy

    The countdown to the USTR for 2017 Special 301 Review has begun

  • Beyond the budget

    The hype around the Union Budget 2017-18, especially after Prime Minister Modi's December 31 address was high but the general consensus is that it has...

  • Pharma PSUs: Missed opportunity?

    The turnover of the Indian pharmaceutical industry was estimated at Rs 2,04,627.1 crores in FY2015-16, registering a growth of 29 per cent compared to the...

  • Giving with a purpose

    ‘He who has health, has hope; and he who has hope, has everything,’ said Thomas Carlyle, social commentator and philosopher

  • More pain before the gain

    An ICRA quarter update on the pharmaceutical sector does not have very encouraging news for 2017

  • Girding up for a VUCA world

    The term VUCA, an acronym for volatility, uncertainty, complexity and ambiguity, was reportedly first coined by the US Army War College to describe the condition...

  • More power to GST

    The ongoing winter session of Parliament is crucial as there are many big ticket bills awaiting a nod

  • India Pharma Inc’s Trump card

    Donald J Trump has beaten all odds to win the US election, much like the Indian pharmaceutical industry’s hard won rise as the go-to country...

  • In search of sustainable growth

    When Ministers speak like CEOs, industry sits up and listens. The relatively newly minted state of Telangana is racing to catch up to its peers...

  • Abiding by the rules

    The debate about replacing PET packaging with glass as packaging material for pharmaceuticals is reaching yet another milestone as the matter is due to come...

  • Opportunities amidst challenges

    MSF’s seven-year-old appeal campaign to reduce flu vaccine prices has finally borne fruit

  • Reviving APIs

    Even as Indian pharmaceutical companies pursue aggressive plans for global expansion, there are deep challenges in the domestic market

  • Thriving through change

    A recently released analysis of the global courier industry from 2010-2021, shows that the pharmaceutical sector accounts for just seven per cent of the sector's global...

  • Testing the new FDI norms

    The Modi government’s reforms have tinkered with FDI norms twice, first in November 2015 and more recently in June this year